AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...

Imfinzi is already approved for extensive-stage SCLC based on the results of the CASPIAN trial, as well as for locally ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...

FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, cutting the risk of death by 27% in the ADRIATIC ...

AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license ...

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer Based on ADRIATIC Phase III trial results which showed a 27 ...

AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed ...

Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease ...